Telmipres 40mg 10pcs

Indications

Telmipres 40 is used to treat a variety of conditions.

Adults with essential hypertension are treated with hypertension medication.

Preventing cardiovascular disease: Adults with atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or Type 2 diabetes mellitus with proven target organ damage should have their cardiovascular morbidity reduced.

Pharmacology

Telmipres 40 inhibits angiotensin II's vasoconstrictor and aldosterone-secreting actions by inhibiting angiotensin II's binding to the AT1 receptor in a variety of tissues, including vascular smooth muscle and the adrenal gland. As a result, it has no effect on the angiotensin II synthesis pathways. Telmisartan binds to the AT1 receptor with a 3,000-fold higher affinity than the AT2 receptor. Telmisartan has no effect on the response to bradykinin since it does not inhibit ACE (kinase II). Telmisartan does not bind to or inhibit any other hormone receptors or ion channels that are known to have a role in cardiovascular control.

Dosage & Administration

Dosage must be individualized. The usual starting dose of Telmisartan tablets is 40 mg once a day. The blood pressure response is dose-related over the range of 20 to 80 mg. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Telmisartan is required, may switch to the combination. No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored. Telmisartan tablets may be administered with other antihypertensive agents. Telmisartan tablets may be administered with or without food. Initial therapy with Telmisartan is not recommended in patients ≥75 years old or with hepatic impairment.

Interaction

Renal impairment and loss of antihypertensive action are more likely with NSAIDs.

Co-administration of aliskiren and Telmisartan should be avoided in diabetic individuals.

Contraindications

Hypersensitivity to this product or any of its ingredients is known.

Side Effects

The most frequent adverse effects of Telmisartan pills in hypertensive individuals are sinus discomfort and congestion (sinusitis), back pain, diarrhea, and others.

Intermittent claudication and skin ulcer are the most prevalent adverse effects of Telmisartan tablets in individuals with cardiovascular risk reduction.

Pregnancy & Lactation

Category C (first trimester) and D (second trimester) pregnancies (second and third trimester). Because of the risk of harmful effects on the nursing infant, consider whether to stop breastfeeding or stop taking the medicine, keeping in mind the drug's value to the mother.

Precautions & Warnings

Avoid exposing a fetus or a newborn.

Hypotension.

Patients with compromised hepatic or renal function should be closely monitored.

Avoid using an ACE inhibitor and an angiotensin receptor blocker at the same time.

Storage Conditions

Do not store at temperatures above 30°C. Light and excessive humidity should be avoided. Keep out of children's reach.